DiscGenics

We are excited to announce that the U.S. FDA has allowed Phase III clinical evaluation of our allogeneic, injectable disc progenitor #celltherapy (IDCT) for painful lumbar #degenerativediscdisease to proceed. Subject enrollment expected to begin Q4 2024. bit.ly/3xX8cv4

DiscGenics Chairman & CEO @flagg_flanagan to present at #CanaccordGenuity 2024 Musculoskeletal Conference prn.to/4bxu7ro #aaos2024

Thrilled to share highlights from our recent podcast with Merge Medical! Dive into the innovative world of DiscGenics and discover the transformative potential of IDCT. A must-listen for those passionate about the future of spinal health! #IDCT #RegenerativeMedicine #SpinalHealth

FDA grants Regenerative Medicine Advanced Therapy (#RMAT) designation to IDCT because of its potential to address the unmet medical needs of millions of patients with painful #degenerativediscdisease! bit.ly/IDCT_RMAT

Our CEO & Chairman @FlanaganFlagg will present an update on our recently completed US clinical study evaluating IDCT for #degenerativediscdisease at the 41st Annual J.P. Morgan Healthcare Conference on Wed., Jan 11, 2023 at 3:30PM. #JPM23 #JPM2023 prn.to/3i9REIc

#DiscGenics Senior Process Engineer is in Dublin this week presenting at the Global Bioprocessing, Bioanalytics & ATMP Manufacturing Congress (@lifesciences_GE) on container closure integrity testing for #celltherapy. global-engage.com/event/biop…

Positive interim clin data for allogeneic #celltherapy for #degenerativediscdisease presented at #SpineSummit2022. High dose IDCT well tolerated, resulted in statistically significant, clinically meaningful improvements in pain, function & quality of life bit.ly/3tcqRwf

Our CEO & Chairman Flagg Flanagan will present an update on our US and Japanese clinical programs evaluating IDCT for #degenerativediscdisease at the 40th Annual J.P. Morgan Healthcare Conference on Tues., Jan 11, 2022 at 9:00AM EST. #JPM22 #JPM2022 bit.ly/DGxJPM22

We are pleased to announce our participation in #CGMesa21 this week. Our Chairman & CEO Flagg Flanagan will give an update on the company’s U.S. and Japanese clinical programs evaluating IDCT for #degenerativediscdisease TODAY at 3:15PM PT. Learn more meetingonthemesa.com

Excited to participate in the #ORS2021 virtual meeting! Our head of R&D will chair 2 Innovation & Commercialization sessions focused on regulatory & manufacturing considerations for orthopaedic product development. #celltherapy #discdegeneration #degenerativediscdisease